Vruzhaj, I.; Gambirasi, M.; Busato, D.; Giacomin, A.; Toffoli, G.; Safa, A.
Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer. Medicina 2025, 61, 633.
https://doi.org/10.3390/medicina61040633
AMA Style
Vruzhaj I, Gambirasi M, Busato D, Giacomin A, Toffoli G, Safa A.
Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer. Medicina. 2025; 61(4):633.
https://doi.org/10.3390/medicina61040633
Chicago/Turabian Style
Vruzhaj, Idris, Marta Gambirasi, Davide Busato, Aurora Giacomin, Giuseppe Toffoli, and Amin Safa.
2025. "Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer" Medicina 61, no. 4: 633.
https://doi.org/10.3390/medicina61040633
APA Style
Vruzhaj, I., Gambirasi, M., Busato, D., Giacomin, A., Toffoli, G., & Safa, A.
(2025). Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer. Medicina, 61(4), 633.
https://doi.org/10.3390/medicina61040633